Examkin

Question

Difficulty: HardInfectious Diseases

A 68-year-old man is evaluated in the intensive care unit on his fifth day of mechanical ventilation. He originally presented with severe acute pancreatitis complicated by acute respiratory distress syndrome. Three days ago, he developed a temperature of 39.2∘C39.2^\circ\text{C} (102.6∘F102.6^\circ\text{F}), increased purulent endotracheal secretions, and a new right lower lobe infiltrate on chest radiograph. He was diagnosed with ventilator-associated pneumonia and empirically started on intravenous vancomycin, cefepime, and tobramycin. Today, his temperature is 37.4∘C37.4^\circ\text{C} (99.3∘F99.3^\circ\text{F}), and his oxygen requirements have decreased. The endotracheal aspirate culture from three days ago grows heavy growth (>105 CFU/mL>10^5\text{ CFU/mL}) of *Klebsiella pneumoniae*. Susceptibility testing reveals resistance to ampicillin, but susceptibility to ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem. Blood cultures are negative. Which of the following is the most appropriate next step in this patient's antimicrobial management?

  1. Discontinue vancomycin and tobramycin; change cefepime to intravenous ceftriaxoneAnswer
  2. B
    Discontinue vancomycin and tobramycin; continue intravenous cefepime
  3. C
    Discontinue vancomycin and tobramycin; change cefepime to intravenous piperacillin-tazobactam
  4. D
    Discontinue vancomycin and tobramycin; change cefepime to intravenous meropenem
  5. E
    Continue intravenous vancomycin, cefepime, and tobramycin without modifications

Answer

The most appropriate step is to discontinue vancomycin and tobramycin, and change cefepime to intravenous ceftriaxone.
The correct answer demonstrates proper antimicrobial stewardship through de-escalation. The patient was appropriately started on a broad-spectrum empiric regimen (vancomycin for MRSA, cefepime and tobramycin for double anti-pseudomonal coverage) for ventilator-associated pneumonia. Now that the patient is clinically improving and culture data reveals a single pathogen (*Klebsiella pneumoniae*) that is susceptible to standard beta-lactams, the empiric regimen must be narrowed. Vancomycin and tobramycin should be discontinued because neither MRSA nor *Pseudomonas aeruginosa* was isolated. Among the susceptible beta-lactams, ceftriaxone is a third-generation cephalosporin with excellent activity against wild-type *Klebsiella pneumoniae* but lacks anti-pseudomonal activity. It is the narrowest effective agent listed. Transitioning from cefepime (a fourth-generation cephalosporin with anti-pseudomonal activity) to ceftriaxone is the optimal stewardship intervention.

Step-by-Step Solution

1
Evaluate the clinical trajectory and need for continued empiric therapy.
The patient's fever has resolved and oxygenation has improved, indicating clinical stability and appropriateness for antimicrobial de-escalation.
De-escalation should be performed once a patient is clinically improving and culture data becomes available.
2
Interpret the culture and susceptibility results.
The pathogen is Klebsiella pneumoniae, susceptible to multiple beta-lactams but not ampicillin. There is no MRSA or Pseudomonas aeruginosa present.
Identifying the specific pathogen allows for discontinuation of agents covering organisms not present in the culture.
3
Apply principles of antimicrobial stewardship to select definitive therapy.
Vancomycin (MRSA coverage) and tobramycin (double Gram-negative/Pseudomonal coverage) must be stopped. Cefepime must be narrowed.
Maintaining unnecessary broad-spectrum agents increases the risk of adverse effects and antimicrobial resistance.
4
Select the narrowest effective agent for the identified organism.
Ceftriaxone is chosen over cefepime, piperacillin-tazobactam, and meropenem.
Ceftriaxone provides targeted therapy for wild-type Klebsiella pneumoniae without exerting selective pressure for Pseudomonas or anaerobic resistance.

Key Concept

Antimicrobial stewardship dictates that empiric broad-spectrum therapy for hospital-acquired infections should be narrowed to the most targeted, definitive agent once culture and susceptibility data are available and clinical improvement is noted.
Estimated Time:2m 0s
Rate this question

Topics

Infectious Diseases

More questions from this topic